Functional studies conducted in GP2-expressing pancreatic cancer cell lines demonstrated that rs78193826 may impact the activity of KRAS, a key driver of pancreatic cancer (with mutation frequencies >93%) [115]. This evidence concerns the gene KRAS and pancreatic neoplasm.